Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review

Abstract

Prostate cancer (PCa) is one of the most common cancers in men that usually develops slowly. Since diagnostic methods improved in the last decade and are highly precise, more cancers are diagnosed at an early stage. Active surveillance or watchful waiting are appealing approaches for men diagnosed with low-risk prostate cancer, and they are an antidote to the overtreatment problem and unnecessary biopsies. However, treatment depends on individual circumstances of a patient. Older hormonal therapies based on first generation antiandrogens and steroids were widely used in metastatic castration-resistant prostate cancer (mCRPC) patients prior to the implementation of docetaxel. Nowadays, accordingly to randomized clinical trials, abiraterone, enzalutamide, apalutamide. and docetaxel became first line agents administrated in the treatment of mCRPC. Furthermore, radium-223 is an optional therapy for bone-only metastasis patients. Sipuleucel-T demonstrated an overall survival benefit. However, other novel immunotherapeutics showed limitations in monotherapy. Possible combinations of new vaccines or immune checkpoint blockers with enzalutamide, abiraterone, radium-223, or docetaxel are the subject of ongoing rivalry regarding optimal therapy of prostate cancer.

Curcumin and Capsaicin: From Spices to Cancer-Suppressing Agents

“…Prostate cancer (PC) is a relevant cause of disease worldwide, being the most commonly diagnosed cancer in men and the fifth most common cause of cancer death globally (PERNAR et al, 2018). According to Malinowski et al (2019) (VENIER et al, 2015).…”

Artikel Review: Interaksi Silang Pensinyalan Wnt dan TGF-β pada Kanker Prostat

“…18 Perubahan keseimbangan hormon testosteron dengan estrogen memiliki pengaruh terhadap diferensiasi dan proliferasi sel, dan diferensiasi sel yang terganggu menyebabkan terjadinya perubahan materi genetik yang lalu berakibat pada produksi sel stroma dan sel epitel kelenjar prostat yang berlebihan, sehingga menyebabkan terjadinya kanker prostat. 16,18,20…”

Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells

“…Prostate cancer preferentially metastasizes to bone, leading to complications including severe pain, fractures, spinal cord compression and bone marrow suppression [5] , [6] – 7] . Treatment strategies of prostate cancer include surgical removal, chemotherapy, hormonal, castration, immunotherapy, and radioisotope therapies [8] , [9] , [10] – 11] . There is no effective treatment for bone metastatic prostate cancer.…”